Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.
Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer.
Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.
Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.
Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.
For further information concerning Lilly grant funding,